This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
—I wish to thank you for forwarding a copy of Dr. Murray Weiner's letter, in which he points to an "error of omission" in our article of Dicumarol [bishydroxycoumarin] therapy in myocardial infarction, that appeared in the September, 1954, issue of the A. M. A. Archives of Internal Medicine.He points to the fact that, while we properly dwelled upon the lack of difference in the number of thromboembolic complications between the control and the treated group, no mention was made of the mortality figures in each group, being 10% in the treated group and 21.3% in the untreated.This is neither an error of omission, thus detracting from the value of Dicumarol, nor of commission, to conceal an unknown but possibly beneficial effect of the drug besides that of lowering the prothrombic time. We realized that there was some difference in the mortality rate between the
Feldman L. BISHYDROXYCOUMARIN (DICUMAROL) THERAPY IN MYOCARDIAL INFARCTION. AMA Arch Intern Med. 1955;95(2):354–355. doi:10.1001/archinte.1955.00250080176020
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: